Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auranofin in HIV-infected Subjects on Suppressive ART
NCT02176135Phase 2Withdrawn
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of auranofin in human immunodeficiency virus infection (HIV). Primary endpoint: Safety and Tolerability at 20 weeks. Status: withdrawn.
02
Drugs
auranofin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02176135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176135.